Core Viewpoint - Reborn Bio-B (06938) shares rose over 5%, currently up 5.62% at HKD 72.45, with a trading volume of HKD 6.483 million, following the announcement of the II phase clinical trial approval for its self-developed RBD5044 injection by the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - According to Guosheng Securities (002670), small nucleic acid drugs are entering a robust global development phase, transitioning from technical validation to clinical realization and accelerated commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically yet, the number of research pipelines ranks second to the U.S., covering multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Significant collaborations have emerged, such as the over USD 9 billion partnership between WuXi AppTec and Novartis, and a USD 2 billion platform licensing deal between Reborn Bio and Boehringer Ingelheim, indicating a positive development trend in the industry [1]
瑞博生物-B涨超5% RBD5044 II期临床试验获默示许可 全球小核酸药物迎来蓬勃发展期